Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Aultman Health Foundation — Canton, Ohio
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Miami Valley Hospital — Dayton, Ohio
- Miami Valley Hospital North — Dayton, Ohio
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Ohio: - Local Institution - 007-893-B — Cincinnati, Ohio
- USOR - Oncology Hematology Care - Blue Ash — Cincinnati, Ohio
- Local Institution - 007-893-C — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Mark H. Zangmeister Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
- USO - Oncology Hematology Care — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T — Columbus, Ohio
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Ohio: - Clinical Study Site — Columbus, Ohio
- Clinical Study Sites — Lebanon, Ohio
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Ohio: - Oncology Hematology Care (OHC), Inc — Cincinnati, Ohio
- University Hospitals Case Medical Center — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Ohio: - Research Site — Cincinnati, Ohio
- Research Site — Columbus, Ohio
- Research Site — Maumee, Ohio
- Research Site — Toledo, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in Ohio: - Oncology Hematology Care, Inc — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Ohio: - University of Cincinnati Medical Center ( Site 0119) — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Ohio: - Local Institution - 0369 — Canton, Ohio
- Local Institution - 0486 — Centerville, Ohio
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Local Institution - 0199 — Cleveland, Ohio
- Local Institution - 0366 — Massillon, Ohio
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Ohio: - Miami Valley Hospital - 1115 — Centerville, Ohio
- University of Cincinnati Cancer Center - 1107 — Cincinnati, Ohio
- The Ohio State University James Cancer Center - 1104 — Columbus, Ohio
- Tri County Hematology & Oncology Associates, Inc - 1156 — Massillon, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Ohio: - Cleveland Clinic Foundation (Adults and Pediatrics) — Cleveland, Ohio
- Nationwide Children's Hospital (Pediatrics only) — Columbus, Ohio
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics) — Columbus, Ohio
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Ohio: - Toledo Clinic Cancer Center - Toledo — Toledo, Ohio
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Ohio: - University Hospitals Seidman Cancer Center — Sandusky, Ohio
- Taylor Cancer Research Foundation — Toledo, Ohio
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 2, Phase 3 Recruiting Industry
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…
Sponsor: AbbVie
NCT ID: NCT06236438
Sites in Ohio: - Oncology Hematology Care, Inc - Blue Ash /ID# 262733 — Cincinnati, Ohio
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Ohio: - University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103) — Cincinnati, Ohio
- Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106) — Kettering, Ohio
Phase 2, Phase 3 Recruiting Industry
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…
Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in Ohio: - The Cleveland Clinic Foundation — Cleveland, Ohio
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Ohio: - Strecker Cancer Center-Belpre — Belpre, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Adena Regional Medical Center — Chillicothe, Ohio
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Ohio: - Mercy Health - Perrysburg Cancer Center /ID# 270536 — Perrysburg, Ohio
- Genesis Healthcare System /ID# 273361 — Zanesville, Ohio
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Ohio: - Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 2 Recruiting NIH
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care trea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05198830
Sites in Ohio: - Case Western Reserve University — Cleveland, Ohio
- MetroHealth Medical Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…
Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Ohio: - University Hospitals Cleveland — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 2 Recruiting Academic/Other
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the effic…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT06773910
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
- Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center — Columbus, Ohio